Bone marrow suppression after strontium-89 therapy and local radiation therapy in patients with diffuse marrow involvement

Clinical Nuclear Medicine

Volumn 22, Issue 3, 1997, Pages 147-150

  Powsner, Rachel A ^a   Zietman, Anthony L ^a   Foss, Francine M ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

bone marrow suppression; Sr 89 therapy

Indexed keywords

LEUPRORELIN; STRONTIUM 89;

ADULT; ARTICLE; BONE MARROW METASTASIS; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CASE REPORT; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MALE; THROMBOCYTE COUNT;

BONE MARROW; BONE MARROW NEOPLASMS; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PAIN; RADIOTHERAPY; STRONTIUM RADIOISOTOPES; THROMBOCYTOPENIA;

EID: 0030939948     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199703000-00002     Document Type: Article

References (4)

1. Breen SL, Powe JD, Porter AT: Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med 33:1316, 1992.
2. Robinson RG, Preston DF, Baxter KG, et al: Clinical experience with strontium-89 in prostatic and breast cancer patients. Sem Oncol (Supplement 2) 20:44, 1993.
3. McEwan AJB, Porter AT, Venner PM, et al: An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy. Antibody Immunol Radiopharm 3:91, 1990.
4. 89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasizing prostatic carcinoma. Eur J Nuc Med 13:41, 1987.